Translational Lung Cancer Research

Papers
(The H4-Index of Translational Lung Cancer Research is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series71
Pushing the boundaries of minimally invasive surgery67
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer52
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report51
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer43
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors41
End-to-side anastomosis in complex tracheal resection and reconstruction: a case series study40
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–203031
Menstrual factors, reproductive history, and risk of lung cancer: a multi-center population-based cohort study in Chinese females30
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report29
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer29
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer28
Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays27
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)27
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer25
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review25
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy25
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network25
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?24
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?24
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression23
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions22
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma22
The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer22
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer—thoughts from the KEYNOTE-671 trial22
Dynamic change of CD8+ T cell: immunotherapy fate tell?22
Real-world data on severe lung cancer: a multicenter retrospective study22
0.049781084060669